APR-246 is currently being tested in combination with carboplatin and pegylated doxorubicin in a phase Ib/II clinical study in HGS ovarian cancer, a tumor type with a 95% frequency of TP53 mutations (see www.clinicaltrials.gov). The gene discussed is TP53; the disease is ovarian cancer.